Loading
A phase 2 trial of temozolomide and olaparib in triple-negative breast cancer, run by AHS Cancer Control Alberta, not yet recruiting.
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) is a phase 2, randomised interventional study registered as NCT05128734 by AHS Cancer Control Alberta, with a registry enrolment figure of 40 participants, started 2026-04-01 and due to reach its primary completion in 2028-04-01. Interventions recorded: Temozolomide; Olaparib. Conditions listed: Breast Cancer Triple Negative. Triple-negative eligibility wording from the registry: "* Female or male patients with triple negative breast cancer confirmed by pathology of the primary tumour or metastatic biopsy sample". Sites: Canada. No results are recorded here; the registry entry is the source.
Shares PARP inhibitors, Olaparib, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.